Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 15

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 15
---
 and -1.1% AER , -4.3% CER ).

Core Share of Profit of Investments Accounted for Using the Equity Method

Core Share of Profit of Investments Accounted for Using the Equity Method was JPY 1.5 billion (JPY -2.8 billion and -65.2% AER , -66.7% CER ).

#### Core Profit Before Tax
Core Profit Before Tax was JPY 901.6 billion (JPY +139.0 billion and +18.2% AER , +11.7% CER ).

#### Core Income Tax Expenses
Core Income Tax Expenses were JPY 202.6 billion (JPY +83.6 billion and +70.3% AER , +64.5% CER ). The increase was due to higher pretax earnings and higher core tax charges including those from the write-down of deferred tax assets recognized during the nine-month period ended December 31, 2024.

#### Core

#### EPS
Core EPS was JPY 443 (JPY +31 and +7.5% AER, +0.9% CER).

<div align='center'>8</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Nine-month

Period Ended December 31, 2024 (Consolidated)

### (2) Consolidated Financial Position
(i) Assets, Liabilities and Equity

|                   |     | As of | March 31, 2024 |     |     | December 31, 2024 |     | Change |        | Billion JPY |
|:------------------|:----|:------|---------------:|:----|:----|------------------:|:----|:-------|-------:|:------------|
| Total Assets      |     |       |       15,108.8 |     |     |          15,106.8 |     |        |   -1.9 |             |
| Total Liabilities |     |       |        7,834.8 |     |     |           7,687.7 |     |        | -147.1 |             |
| Total Equity      |     |       |        7,274.0 |     |     |           7,419.2 |     |        |  145.2 |             |

#### Assets
Total Assets as of December 31,